Share

June 2016; 3 (3) ArticleOpen Access

Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis

Petra Bergman, Eliane Piket, Mohsen Khademi, Tojo James, Lou Brundin, Tomas Olsson, Fredrik Piehl, Maja Jagodic
First published April 20, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000219
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1202

Share

Article Information

vol. 3 no. 3 e219
DOI: 
https://doi.org/10.1212/NXI.0000000000000219
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received October 2, 2015
  • Accepted in final form February 1, 2016
  • First Published April 20, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Petra Bergman, PhD,
    2. Eliane Piket,
    3. Mohsen Khademi, PhD,
    4. Tojo James,
    5. Lou Brundin, MD, PhD,
    6. Tomas Olsson, MD, PhD,
    7. Fredrik Piehl, MD, PhD and
    8. Maja Jagodic, PhD
  1. Petra Bergman, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Eliane Piket,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Mohsen Khademi, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Tojo James,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Lou Brundin, MD, PhD,
    6. Scientific Advisory Boards:

    1. Advisory board Genzyme Advisory board Biogen

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. ECTRIMS summer school teaching Speaker honoraria from Biogen and Genzyme

    Editorial Boards:

    1. Information written for the Swedish MPA on MS treatment

    Patents:

    1. NONE

    Publishing Royalties:

    1. Chapter on spinal cord injury in the Swedish Brain Fund book

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. Participated in an airline commercial (SAS)

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Swedish MRC K2013-62X-20724-06-3 Karolinska Institutet Stockholm County

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Soderberg Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Tomas Olsson, MD, PhD,
    7. Scientific Advisory Boards:

    1. scientific advisory boards: Merck-Serono 2008-2010, BiogenIdec 2006- 2014 and Genzyme/SanofiAventis 2006-2014, Novartis 2009-2014. With all of them advice with regard to therapy in multiple sclerosis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. For lectures on Multiple sclerosis, Novartis 2008 and BiogenIdec 2006, 2007, 2008, 2009, 2010 , 2011 and 2012. SanofiAventis and Merck 2010, Genzyme 2012 and 2013.Medimmune 2013

    Editorial Boards:

    1. Co-editor 2006 in Current opinion in Immunology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1)Merck, 2)BiogenIdec, 3)SanofiAventis, 4)Bayer, 5) Novartis,6)AstraZeneca

    Research Support, Government Entities:

    1. Tomas Olsson (TO) has received grant support from The Swedish Research council (07488), EU fp7, Euratrans Neurinox 2012-2015 and combiMS, 2013-2014, Swedish Brain foundation,the AFA foundation, Knut and Alice Wallenberg foundation.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. The Knut and Allice Wallenberg foundation, The Swedish Brain foundation, the AFA foundation, EU FP 7 Neurinox and EURATrans projects.TO has also received unrestricted research grants from Bayer Schering, Genzyme/Sanofi-AventisBiogen Idec and AstraZeneca.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Fredrik Piehl, MD, PhD and
    8. Scientific Advisory Boards:

    1. data safety monitoring committee Parexel/Chugai

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. 1. Biogen - unrestricted academic research projects outside of this study 2. Novartis - unrestricted academic research projects outside of this study 3. Genzyme - unrestricted academic research projects outside of this study

    Research Support, Government Entities:

    1. Swedish Medical Research Council (grant 2014-3077) PI, 2013-ongoing

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Maja Jagodic, PhD
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Physiological Genomics, Editorial Board member, 2015-2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) AstraZeneca (AstraZeneca-Science for Life Laboratory collaboration), co-investigator, 2014-2017

    Research Support, Government Entities:

    1. (1) The Swedish Research Council, lead investigator, K2015-61X-20776-08-3, 2015-2018 (2) The Swedish Research Council, lead investigator, K2012-99X-20776-05-3, 2012-2014 (3) The regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, lead investigator, 2014-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) The Swedish Association for Persons with Neurological Disabilities, co-investigator (2) The Swedish Brain Foundation, main investigator (3) The Swedish Medical Society, main investigator (4) Petrus and Augusta Hedlunds Foundation, main investigator

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
  1. Correspondence to Dr. Jagodic: maja.jagodic{at}ki.se
View Full Text

Article usage

Article usage: April 2016 to June 2019

AbstractFullPdfSource
Apr 201614014929Highwire
May 201623926666Highwire
May 2016012976pmc
Jun 201627429771Highwire
Jun 2016011947pmc
Jul 2016862533Highwire
Jul 201605439pmc
Aug 2016463317Highwire
Aug 201605340pmc
Sep 201642123Highwire
Sep 201607330pmc
Oct 201655119Highwire
Oct 201609233pmc
Nov 2016292814Highwire
Nov 201607128pmc
Dec 201630710Highwire
Dec 201604314pmc
Jan 2017351010Highwire
Jan 201705317pmc
Feb 20172296Highwire
Feb 20170237pmc
Mar 2017201410Highwire
Mar 201706453pmc
Apr 201719143Highwire
Apr 2017183458pmc
May 201716711Highwire
May 2017214139pmc
Jun 201713613Highwire
Jun 201742327pmc
Jul 20171536Highwire
Jul 201741616pmc
Aug 20171443Highwire
Aug 201771823pmc
Sep 20171264Highwire
Sep 2017173956pmc
Oct 20171428Highwire
Oct 2017132428pmc
Nov 20171689Highwire
Nov 2017162425pmc
Dec 201731711Highwire
Jan 20181384Highwire
Feb 20181103Highwire
Mar 20184217Highwire
Apr 20183248Highwire
Apr 2018142332pmc
May 20181464Highwire
Jun 20183428Highwire
Jun 201891617pmc
Jul 201851252Highwire
Aug 2018114314Highwire
Aug 201861920pmc
Sep 201841205Highwire
Oct 201811077Highwire
Nov 2018110410Highwire
Dec 201831862Highwire
Jan 201961509Highwire
Feb 2019616312Highwire
Mar 20194647Highwire
Apr 20192318Highwire
May 201932715Highwire
Jun 20198346Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Topics Discussed

Alert Me

Advertisement